Wearable Parkinson’s monitor uses AI to detect symptoms

thank you. Listen to this article using the player above. ✖

Results from a multicenter clinical study analyzing the performance of PDMonitor, PD Neurotechnology’s pioneering Parkinson’s disease monitoring device that uses wearables and artificial intelligence (AI) to track and assess symptoms, are published today. frontiers of neurologya leading peer-reviewed journal of clinical neurology.

This study compared the automatic assessment of Parkinson’s disease patients in three European hospitals by PDMonitor with physicians’ clinical assessments and symptom diaries to determine whether the device is a reliable and feasible means of informing treatment plans. I judged PDMonitor collects data on symptom timing and severity using her five sensors worn on the patient’s trunk and extremities, and uses machine learning algorithms to complete the assessment.

Statistical analysis demonstrated a high level of accuracy in symptom detection and a strong correlation with expert assessment in assessing symptom severity. PDMonitor achieved over 99 percent accuracy and specificity levels in detecting mild-to-severe dyskinesias, gait disturbances, wrist and leg tremors, and “off” periods when Parkinson’s symptoms recur between medications. achieved an accuracy and specificity level of at least 96 percent.

A second study (details of which were also published in Frontiers in Neurology) found that the PDMonitor was effective and easy to use for patients and caregivers, even in patients with late-stage disease. was found to take only 5 minutes on average. disease. We found that the usability of the device was further improved by automatically recording and identifying the location of each sensor on the patient’s body.

These peer-reviewed papers are part of a growing body of evidence highlighting PDMonitor’s accuracy and effectiveness. Preliminary findings from data analysis on 267 patients in Greece provide evidence that continuous telemonitoring in clinical settings can lead to symptomatic relief of Parkinson’s disease. The average “off” time experienced by patients in this study decreased for two consecutive quarters after the introduction of PDMonitor.

In January 2023, PDMonitor became one of four devices conditionally recommended for remote monitoring of Parkinson’s disease to provide treatment information by NICE (National Institute for Health and Care Excellence) . This decision opens the door for the use of her PDMonitor by NHS patients and their doctors in the UK.

Nikos Moskos, Managing Director of PD Neurotechnology, commented: Research confirms this tool is effective and easy to use, and time and time again we have seen how it facilitates better treatment decisions for patients based on real data. By providing accurate and continuous symptom data and an ecosystem to effectively collect and present it, we aim to continually improve the management of Parkinson’s disease and hopefully improve the quality of life for patients. I’m here. ”

Professor K Ray Chowdhury, Director of the Parkinson’s Disease Foundation Center of Excellence at King’s College Hospital, who is piloting PDMonitor in private patients from March 2022, commented: social cost. A patient’s quality of life and well-being is highly dependent on consistent and rapid monitoring of disease progression and optimal timing and dosage of prescribed therapy. ”

“PDMonitor supports a new paradigm shift in Parkinson’s disease treatment by augmenting the traditional short-term face-to-face consultation with home monitoring, which has many of the same benefits as diabetes and heart disease monitoring.

“Continuous monitoring of patients at home as they go about their daily activities will enable more frequent treatment decisions and help physicians respond more quickly to changes in symptoms.

“A major advantage of PDMonitor is that it can provide patients with a self-monitoring platform, in addition to monitoring gait and fall risk. is a key feature of

“There is no cure for Parkinson’s disease, but it is possible to slow the progression of symptoms and reduce the risk of falls. Mobility, falls, and related fractures remain the leading causes of Parkinson’s morbidity and hospitalization. Therefore, judicious use of PD Monitor data means accurate assessment with snapshots of home activity to provide dashboard-based, personalized care.”

reference: Antonini A, Reichmann H, Gentile G, and others. Toward objective monitoring of motor symptoms in Parkinson’s disease by wearable devices: wearability and performance evaluation of PDMonitor®. front new roll. 2023;14:1080752. Doi: 10.3389/fneur.2023.1080752

This article is reprinted from: Note: Materials may have been redacted for length and content. Please contact the citation source for details.